Acumen Pharmaceuticals, Inc. ABOS

2.24 0.00 0.00% as of 25 Sep
Market cap
$161.6M
P/E
0.0×
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 0.00 — — — — —
P/S ratio
— 6.05 6.05 — — — — —
P/FCF ratio
— 0.00 0.00 — — — — —
P/Operating CF
— (2.04) (2.04) — — — — —
P/B ratio
— 0.00 0.00 — — — — —
EV/Sales
— (41.87) (41.87) — — — — —
EV/EBITDA
— 5.43 5.43 — — — — —
EV/FCF
— 5.58 5.58 — — — — —
Current Ratio
— 9.38 46.57 38.60 23.08 19.01 6.46 4.07
Net Debt/EBITDA
— 0.84 5.53 10.00 3.98 3.33 1.20 0.69
Debt/Equity
— 0.00 0.00 0.00 0.00 0.11 0.16 0.44
ROE
— 51.22% 48.82% (97.40%) (20.71%) (22.98%) (45.60%) (96.20%)
ROA
— (209.94%) (28.31%) (73.23%) (20.08%) (20.67%) (37.27%) (67.07%)
ROIC
— 0.00% 0.00% (39.55%) (250.76%) (71.63%) (179.60%) 0.00%
Return on Tangible Assets
— (119.85%) (16.85%) (51.98%) (24.82%) (22.40%) (67.90%) (131.54%)
Average Days of Receivables
— 6.45 27.71 — — — — —
Earnings Yield
— (1,065.13%) (1,065.13%) — — — — —
Free Cash Flow Yield
— (124.08%) (124.08%) — — — — —
Free Cash Flow per Share
— (15.83) (17.78) (0.90) (0.87) (0.89) (1.44) (1.91)
Book value per Share
— (26.51) (44.37) 11.23 4.65 5.49 3.03 1.16
Free Cash Flow
— (6.82) (7.45) (18.00) (35.31) (43.08) (86.23) (115.63)
EV/EBIT
— 5.43 5.43 — — — — —
Other line items

Show all line items

Columns are period end dates